CML Partnership 091012c
You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.
You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.
If you do not wish to leave this site, click Cancel. Or, click OK to continue.
Cancel
OK >
Treatment of Ph+ CML
Advancing Science
Advancing Care
Future goals for Ph+ CML patients are being shaped by an actively evolving paradigm.
Stay up to date with these interactive assets.
Explore the evolution
of Ph+ CML care
Find out more about early
therapies, important milestones,
and the new era of advanced care
Learn more >
A guide to read and interpret IS RQ-PCR reports
Learn how IS RQ-PCR results track progress and inform treatment decisions
The importance of the International Scale for RQ-PCR
A deeper look at why the International Scale is used to standardize results
Watch a new video on Ph+ CML care
The mechanism of the disease provides a crucial learning for treating Ph+ CML
- Learn More >
Maecenas non auctor est. Aliquam erat
Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.
- Learn More >
Proin egestas tellus sit amet mi
Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.
- Learn More >
Curabitur nisi est, consectetur eu mollis
Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.
- Learn More >
For information about a free trial of IS RQ-PCR, call MolecularMD at 877-459-4979 or
Genoptix at 800-755-1605 and ask about GET RQ-PCR NOW.
To learn more about Ph+ CML treatment options, click here.
Glossary
AP=accelerated phase. BC=blast crisis. BCR-ABL=breakpoint cluster region-abelson. Ph+ CML=Philadelphia chromosome-positive chronic myeloid leukemia. CBC=complete blood count. CHR=complete hematologic response. mCyR=major cytogenic response. PCyR=partial cytogenetic response. CCyR=complete cytogenetic response. FISH=fluorescence in situ hybridization. ELN=European Leukemia Net. MMR=major molecular response. MR=molecular response. MRD=minimal residual disease. NCCN=National Comprehensive Cancer Network. IS=International Scale. RQ-PCR=real-time quantitative polymerase chain reaction. TKI=tyrosine kinase inhibitor.
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080 © 2012 Novartis 08/12 T-CDE-1047709
